The role of radiotherapy in the treatment of prostatic cancer;Place de la radiothérapie dans le traitement du cancer de la prostate

Medecine et Hygiene

Volumn 61, Issue 2461, 2003, Pages 2386-2388

  Zouhair, Abderrahim ^a   Mirimanoff, René Olivier ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; PROGNOSIS; PROSTATE CANCER; RADIATION BEAM; RADIATION DOSE DISTRIBUTION; REVIEW; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME;

EID: 0346882539     PISSN: 00256749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Keeley FX, Gomella LG. Epidemiology of prostate cancer. In: Ernstoff MS. Heaney JA. Peschel RE (Eds). Prostate cancer. Oxford: Blackwell Science. 1998; 1-4.
2. Peshel RE, Colberg JW. Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol 2003; 4: 233-41.
3. Perez CA, Garcia D, Simpson JR, et al. Factors influencing outcome of definitive radiotherapy for localized carcinoma of the prostate. Radiother Oncol 1989; 16: 1-21.
4. Perez CA, Michalski JM, Purdy JA, et al. Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: Preliminary results of a non randomised comparison. Int J Radiat Oncol Biol Phys 2000; 47: 629-37.
5. Koper PC, Stroom JC, van Putten WL, et al. Acute morbidity reduction using 3 DCRT for prostate carcinoma: A randomized study. Int J Radiat Oncol Biol Phys 1999; 43: 727-34.
6. Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: A randomised trial. Lancet 1999; 353: 267-72.
7. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74.
8. Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis. JAMA 1999; 281: 1598-604.
9. Pollack A, Smith LG, von Eschenbach AC. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys 2000; 48: 507-12.
10. Hanks GE, Hanlon AL, Pinover WH, et al. Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 2000; 46: 823-32.
11. Peschel RE. Three-dimensional conformal radiation therapy for early prostate cancer. Cancer J Sci Am 1999; 5: 145-6.
12. Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomised radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 2000; 23: 3904-11.
13. Consensus statements on radiation therapy of prostate cancer: Guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. J Clin Oncol 1999; 4: 1155-63.
14. Bagshaw MA, Cox RS, Ray GR. Status of radiation treatment of prostate cancer at Stanford University. Monogr Cancer Inst 1988; 7: 47-60.
15. Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomised dose-escalation study comparing 70 Gy to 78 Gy for the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1999; 45: 146.
16. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300.
17. Bolla M, Colette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial. Lancet 2002; 360: 1038.
18. Zurlo A, Colette L, van Tienhoven G, et al. Acute toxicity of conventional radiation therapy for high-risk prostate cancer in EORTC trial 22863. European Urology 2002; 42: 125-32.
19. Pilepich M, Winter K, Roach M, et al. Phase III radiation therapy oncology group trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1998; 42: 177.
20. Lawton CA, Winter K, Murray K, et al. Updated results of phase III radiation therapy oncology group 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavourable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 4: 937-46.
21. Horwitz EM, Winter K, Hanks GE, et al. Subset analysis of RTOG and 86-10 indicates an advantage for long-term vs short-term adjuvant hormones for patients with locally advanced non metastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 2001; 4: 947-56.
22. Roach III M, Desilvio M, Lawton V, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 94-13. JCO 2003; 10: 1904-11.
23. Ash D, Flynn A, Battermann J, et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000; 57: 315-21.
24. Nag S, Beyer D, friedland J, et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999; 44: 789-99.
25. Ragde H, Blasko JC, Grimm PD, et al. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer 1997; 80: 442-53.
26. Terk MD, Stock RG, Stone NN. Idendtication of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 1998; 160: 1379-82.
27. Chow E, Wu JSY, Hoskin P, et al. International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol 2002; 64: 275-80.